ProPhase Labs director Warren Hirsch resigns

ProPhase Labs, Inc. reported that Board member Warren Hirsch resigned from the Board of Directors effective immediately on January 5, 2026.

Accepted by SEC EDGAR 01/09/2026 - 05:10 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

ProPhase Labs, Inc. reported that Board member Warren Hirsch resigned from the Board of Directors effective immediately on January 5, 2026. The company states that Mr. Hirsch’s resignation was not due to any disagreement with ProPhase Labs regarding its operations, policies, or practices, indicating an orderly and non-contentious departure. The Board and the company expressed appreciation for his service and contributions during his tenure.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did ProPhase Labs (PRPH) disclose in this 8-K filing?

ProPhase Labs, Inc. disclosed that director Warren Hirsch resigned from its Board of Directors effective January 5, 2026, and that his resignation was not due to any disagreement with the company.

When did ProPhase Labs director Warren Hirsch resign from the Board?

ProPhase Labs reported that Warren Hirsch notified the company of his resignation from the Board of Directors on January 5, 2026, effective immediately.

Did Warren Hirsch resign from ProPhase Labs due to a disagreement?

No. The company states that Mr. Hirsch’s resignation was not the result of any disagreement with ProPhase Labs on matters related to its operations, policies, or practices.

What position did Warren Hirsch hold at ProPhase Labs (PRPH)?

Warren Hirsch served as a member of the Board of Directors of ProPhase Labs, Inc. before his resignation effective January 5, 2026.

How did ProPhase Labs respond to Warren Hirsch’s resignation?

ProPhase Labs expressed its appreciation, noting that the company thanks Mr. Hirsch for his service and contributions during his tenure on the Board.

Who signed the ProPhase Labs 8-K reporting Warren Hirsch’s resignation?

The report was signed on behalf of ProPhase Labs, Inc. by Ted Karkus, who is identified as Chairman of the Board and Chief Executive Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

false 0000868278 0000868278 2026-01-09 2026-01-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 9, 2026

PROPHASE LABS, INC.

(Exact name of Company as specified in its charter)

Delaware		000-21617		23-2577138
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

626 RXR Plaza, 6th Floor Uniondale, New York		11556
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (516) 989-0763

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14(d)-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities Registered Pursuant to Section 12(b) of the Exchange Act:

Title of Each Class		Trading Symbol		Name of Each Exchange of Which Registered
Common Stock, par value $0.0005		PRPH		OTC Markets

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On January 5, 2026, Warren Hirsch notified the Company of his resignation as a member of the Board of Directors of ProPhase Labs, Inc. (the “Company”), effective immediately.

Mr. Hirsch’s resignation was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices.

The Company thanks Mr. Hirsch for his service and contributions during his tenure on the Board.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ProPhase Labs, Inc.
By:	/s/ Ted Karkus
	Ted Karkus
	Chairman of the Board and Chief Executive Officer
Date: Friday, January 9, 2026